For Sale: Merck's Biosimilars Unit

Mar 09, 2017

Reuters

Germany's Merck KGaA confirmed it was looking for a buyer for its biosimilars unit, according to a Reuters article.

CEO Stefan Oschmann said at a recent press conference that negotiations were far advanced but complex.

The article said Merck has been working with Dr Reddy's of India in developing cheaper versions of blockbuster biotech drugs such as AbbVie's (ABBV.N) Humira, Roche's (ROG.S) Rituxan and Amgen's (AMGN.O) Neulasta but has not yet brought products to market.

Read the Reuters story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments